Breakthrough in breast cancer by Irish scientists

Triple negative breast cancer (TBNC) is the most aggressive of all breast cancer occurring in 15% of total breast cancer mainly found in young females. According to a new drug developed, the drug enables the effectiveness of the initial chemotherapy and decreases the relapse amongst women with TBNC. In a study carried out 595 patients with sample revealed that TBNC tumors displayed the highest IRE 1 activity compared to other subtypes. It was discovered that impaired ‘normal stress response’ of health cells was a critical factor. By targeting the stress response pathway- IRE 1 could improve the response to chemotherapy and reduce relapse for patients with TNBC. According to research, they discovered that by blocking IRE 1 activity the production of survival signal decreased in turn reducing the growth of new cancer cells by 50%.